Abiomed Artificial Heart HDE Voted Down By Cardio Panel In Wild Finish
This article was originally published in The Gray Sheet
Executive Summary
Abiomed will give FDA additional anti-coagulation and quality-of-life data from a 14-patient trial supporting the firm's HDE application for the AbioCor total artificial heart, following a negative panel vote
You may also be interested in...
FDA To Poll Pediatricians On Unmet Device Needs
A working group that includes FDA is planning to survey pediatricians on their unmet needs for devices tailored to children, according to Joanne Less, CDRH associate director of clinical research & government affairs
FDA To Poll Pediatricians On Unmet Device Needs
A working group that includes FDA is planning to survey pediatricians on their unmet needs for devices tailored to children, according to Joanne Less, CDRH associate director of clinical research & government affairs
SynCardia Retools To Accelerate Use Of CardioWest Artificial Heart
SynCardia plans to distribute its total artificial heart to at least 10 additional U.S. transplant centers in 2006 now that it has reorganized to support sales and distribution